New kid on the block
This article was originally published in The Tan Sheet
Dynova Laboratories enters the supplement market with the acquisition of SiCaps Industries and its capsaicin-based Sinus Buster brand products. Parsippany, N.J.-based Dynova, backed by the private equity fund Aisling Capital, looks to provide clinical, marketing, packaging and sales support to "novel" dietary supplement products and ingredients with "unique delivery" and "compelling claims," according to Dynova's Web site. The firm led by former Novartis OTC business executives Lynne Millheiser-Swanbeck and Jeff Vernimb, and by Jennifer Cooper, formerly with Twin Laboratories and Solgar...
You may also be interested in...
The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Medicines for Ireland has released a report focusing on the direct impact of Brexit and COVID-19 on the medicines supply chain. The association has called for long-term plans and solutions instead of temporary fixes for issues related to delays in the import and export of medicines.